Gerren McHam, vice president of Government and External Affairs, API Innovation Center, discusses how federal policy is shaping efforts to reshore active pharmaceutical ingredient (API) manufacturing and strengthen domestic capacity. He cites the Clear Labels Act and the Maps Act, noting sponsorship from both Republican and Democratic senators, including Senator Scott, Senator Gillibrand, and Senator Gary Peters. These initiatives collectively aim to strengthen transparency, resilience, and prioritization of domestic production in federal procurement. He notes that both the first Trump administration and the Biden administration, as well as the subsequent Trump administration, have used industrial base management, supply chain authorities, and Defense Production Act tools to bolster a strategic stockpile and an API reserve. In his view, such investments help build foundational capacity but are not sufficient on their own.